Clinical Trial

A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of the dose escalation part of the study is to characterize the safety and tolerability of ALN-BCAT as monotherapy and in combination with pembrolizumab; and to determine the recommended dose(s) for expansion (RDFE) of ALN-BCAT as monotherapy and in combination with pembrolizumab. The purpose of the dose expansion part of the of the study is to evaluate the antitumor activity of ALN-BCAT as monotherapy and in combination with pembrolizumab; to characterize the safety and tolerability of ALN-BCAT as monotherapy and in combination with pembrolizumab.
Protocol Amendment History 19 amendments
This ClinicalTrials.gov record has been amended 19 times since 2024-09-13; most recent amendment 2026-06-16.
Status change: Not Yet Recruiting → Recruiting 2024-10-11
Trial Details
NCT Number NCT06600321
Lead Sponsor Alnylam Pharmaceuticals
Conditions Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma
Enrollment 158 participants
Start Date 2024-12-30
Primary Completion 2027-09-30 (estimated)
Study Completion 2027-10-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-17